article · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics
Yassir BoulaamaneParkinson's disease is the second most frequent neurodegenerative condition, characterised by the loss of mid-brain dopaminergic neurons. Although L-DOPA has long served as the standard treatment for motor symptoms, its therapeutic efficacy diminishes over extended periods, creating an urgent demand for new therapies. Caffeine derivatives are recognised for their neuroprotective effects and ability to block both monoamine oxidase B and adenosine A2A receptors simultaneously. Computational investigations of natural product-like caffeine derivatives identified two top lead compounds, designated CNP0202316 and CNP0365210, that meet the necessary criteria for drugs acting on the brain. Molecular dynamics simulations confirmed the stability of these compounds when interacting with monoamine oxidase B. These natural molecules offer promising foundational structures for the development of dual-action treatments capable of managing symptoms and slowing neuronal damage.
Current treatments for Parkinson's disease, such as L-DOPA, lose efficacy over time and fail to halt progressive neurodegeneration. Identifying natural product derivatives that simultaneously inhibit two key disease targets offers a promising strategy to design more durable therapies that both relieve symptoms and protect brain cells from further deterioration.
This work identifies early-stage computational hits for pharmaceutical companies and medicinal chemistry programmes targeting neurodegenerative disorders. Because the findings derive entirely from in silico screening and molecular dynamics simulations, the compounds are at a very early discovery stage. Substantial laboratory synthesis, biological assays, and preclinical testing will be necessary before these molecules can proceed toward therapeutic development.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Parkinson’s disease is considered the second most frequent neurodegenerative disease. It is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L-DOPA has been considered as the gold standard for treating Parkinson’s disease motor symptoms, however, due to the decrease of efficacy, in the long run, there is an urgent need for novel antiparkinsonian drugs. Caffeine derivatives have been reported several times for their neuroprotective properties and dual blockade of monoamine oxidase (MAO) and adenosine A 2A receptors (AA 2A R). Natural products are currently attracting more focus due to structural diversity and safety in contrast to synthetic drugs. In the present work, computational studies were conducted on natural product-like caffeine derivatives to search for novel potent candidates acting as dual MAO-B inhibitors/AA 2A R antagonists for Parkinson’s disease. Our findings revealed two natural products among the top hits: CNP0202316 and CNP0365210 fulfill the requirements of drugs acting on the brain. The selected lead compounds were further studied using molecular dynamics simulation to assess their stability with MAO-B. Current findings might shift the interest towards natural-based compounds and could be exploited to further optimize caffeine derivatives into a successful dual-target-directed drug for managing and halting the neuronal damage in Parkinson’s disease patients.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1515/jib-2021-0027
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
